查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1580008

困难梭状芽孢桿菌治疗市场：依治疗类型、给药途径、患者年龄层和最终用户 - 2025-2030 年全球预测

Clostridium Difficile Treatment Market by Treatment Type (Antibiotics Treatment, Non-Antibiotic Treatment), Route of Administration (Oral, Parenteral), Patient Age Group, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年，困难梭状芽孢桿菌治疗市值为88.2亿美元，预计2024年将达到94.1亿美元，复合年增长率为6.89%，预计到2030年将达到140.7亿美元。

困难梭状芽孢桿菌治疗市场包括一系列诊断、治疗和预防解决方案，旨在对抗困难梭状芽孢桿菌细菌引起的感染疾病，这种细菌通常会导致严重腹泻和结肠炎。高感染復发率、抗生素抗药性以及与艰难梭菌感染疾病(CDI) 相关的显着发病率推动了对有效治疗的需求。应用领域主要涵盖医疗保健领域，包括医院、专科诊所和长期照护机构。最终用途集中于医疗保健提供者、患者和看护者，寻求减少感染疾病的发生率并改善患者的治疗结果。

主要市场统计
基准年[2023] 88.2亿美元
预测年份 [2024] 94.1亿美元
预测年份 [2030] 140.7亿美元
复合年增长率（%） 6.89%

关键的成长要素包括 CDI 发病率上升、人口老化、住院率上升以及对抗生素相关腹泻的认识提高。此外，微生物组研究和粪便微生物群移植（FMT）的进步正在带来创新的治疗方法。市场看到了开发窄频谱抗生素、有效疫苗和旨在恢復健康肠道菌丛的新型益生菌的潜在机会。然而，先进治疗方法的高成本、严格的监管要求以及与微生物治疗相关的复杂性等限制构成了重大挑战。抗生素抗药性的风险和目前治疗方法的有限有效性进一步加剧了市场的不可预测性。

需要创新的领域包括研究侵入性较小的微生物组修復技术、开发副作用较少的替代疗法，以及早期检测 CDI 发病的有效诊断工具。此外，探索合成生物学以生产靶向噬菌体和工程益生菌作为潜在的治疗方法也具有潜力。由于正在进行的临床研究以及生物技术公司和学术机构之间不断加强的合作，市场的性质仍然高度活跃。为了抓住新的商机，相关人员应投资强大的研发开发平臺，并建立策略伙伴关係关係，以实现创新的快速开发和商业化。保持监管合规性并倡导更透明的报销政策也将有助于缓解市场限制。

市场动态：揭示快速发展的困难梭状芽孢桿菌治疗市场的关键市场洞察

供需的动态交互作用正在改变困难梭状芽孢桿菌药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 困难梭状芽孢桿菌传染病盛行率上升
    • 关注预防策略和益生菌
    • 提高医疗保健意识和治疗困难梭状芽孢桿菌传染病的倡议
  • 市场限制因素
    • 抗生素抗药性和復发率
  • 市场机会
    • 开发标靶治疗
    • 诊断工具和技术的进步
  • 市场挑战
    • 准确诊断的复杂性和法规遵循的限制

波特五力战略工具驾驭困难梭状芽孢桿菌药物市场

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对困难梭状芽孢桿菌治疗市场的影响

外部宏观环境因素在塑造困难梭状芽孢桿菌治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解困难梭状芽孢桿菌治疗药物市场的竞争状况

对困难梭状芽孢桿菌治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位困难梭状芽孢桿菌治疗市场供应商的绩效评估

FPNV 定位矩阵是评估困难梭状芽孢桿菌治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘困难梭状芽孢桿菌治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对困难梭状芽孢桿菌治疗市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 困难梭状芽孢桿菌传染病盛行率上升
      • 关注预防策略和益生菌
      • 提高医疗保健意识和参与治疗困难梭状芽孢桿菌传染病
    • 抑制因素
      • 抗生素抗药性和復发率
    • 机会
      • 开发标靶治疗和先进治疗
      • 诊断工具和技术的进步
    • 任务
      • 准确诊断的复杂性和法规遵循的限制
  • 市场区隔分析
    • 治疗类型：为了降低復发率并儘量减少对肠道菌丛的影响，对非达霉素的需求量很大。
    • 最终使用者：提高医院和诊所困难梭状芽孢桿菌治疗的可用性
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章困难梭状芽孢桿菌治疗药物市场（依治疗类型）

  • 抗生素治疗
    • 非达霉素
    • 甲硝唑
    • 万古霉素
  • 无需抗生素治疗
    • 粪便微生物移植
    • 益生菌

第七章困难梭状芽孢桿菌治疗市场：依给药途径

  • 口服
  • 胃肠外的

第 8 章依病患年龄组别困难梭状芽孢桿菌治疗市场

  • 成人
  • 老年病
  • 小儿科

第 9 章困难梭状芽孢桿菌治疗市场：依最终用户

  • 家庭保健
  • 医院/诊所

第10章美洲困难梭状芽孢桿菌治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章 亚太地区困难梭状芽孢桿菌治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东和非洲困难梭状芽孢桿菌治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Vedanta Biosciences 正在三期试验中推进 VE303，以对抗復发性困难梭状芽孢桿菌传染病，着眼于市场核准和策略投资。
    • 在 FDA核准完成治疗困难梭状芽孢桿菌的 2 期临床试验后，Acurx Pharmaceuticals 正在将 ivezapolstat 推进到 3 期临床试验。
  • 战略分析和建议

公司名单

  • Acurx Pharmaceuticals, Inc.
  • Aridis Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • GlaxoSmithKlinePLC
  • Immuron Limited
  • Merck & Co., Inc.
  • Mylan NV
  • Pfizer, Inc.
  • Rebiotix Inc
  • Roche Holding AG
  • Seres Therapeutics, Inc.
  • Summit Therapeutics, Inc.
  • Synthetic Biologics, Inc.
  • Thermo Fisher Scientific, Inc.
  • Trinity Biotech PLC
  • Vedanta Biosciences, Inc.
Product Code: MRR-AA6346B014A7

The Clostridium Difficile Treatment Market was valued at USD 8.82 billion in 2023, expected to reach USD 9.41 billion in 2024, and is projected to grow at a CAGR of 6.89%, to USD 14.07 billion by 2030.

The Clostridium Difficile Treatment market encompasses a range of diagnostic, therapeutic, and preventive solutions aimed at addressing infections caused by the Clostridium difficile bacterium, which often leads to severe diarrhea and colitis. The necessity for effective treatments is driven by high infection recurrence rates, antibiotic resistance, and the significant morbidity associated with C. difficile infections (CDIs). Application areas primarily span across the healthcare sector, including hospitals, specialty clinics, and long-term care facilities. End-use is concentrated among healthcare providers, patients, and caregivers, seeking to reduce incidences and improve patient outcomes.

KEY MARKET STATISTICS
Base Year [2023] USD 8.82 billion
Estimated Year [2024] USD 9.41 billion
Forecast Year [2030] USD 14.07 billion
CAGR (%) 6.89%

Key growth factors include rising incidences of CDIs, an aging population, increased hospitalization rates, and greater awareness of antibiotic-associated diarrhea. Additionally, advancements in microbiome research and fecal microbiota transplantation (FMT) have spearheaded innovative treatment approaches. The market is witnessing potential opportunities in the development of narrow-spectrum antibiotics, effective vaccines, and novel probiotics aimed at restoring healthy gut flora. However, limitations such as the high cost of advanced therapies, stringent regulatory requirements, and the complexities associated with microbiome-based treatments present significant challenges. The risks of antibiotic resistance and limited efficacy of current treatments further underscore market unpredictability.

Areas ripe for innovation include research into less invasive microbiome restoration techniques, development of alternative therapies with fewer side effects, and more efficient diagnostic tools for early detection of CDI onset. Additionally, there lies potential in exploring synthetic biology for producing targeted bacteriophages or engineered probiotics as promising interventions. The market's nature remains highly dynamic due to ongoing clinical studies and increasing collaboration between biotechnology firms and academic institutions. To seize emerging opportunities, stakeholders should invest in robust R&D pipelines and foster strategic partnerships for faster development and commercialization of their innovations. Maintaining regulatory compliance and advocating for more transparent reimbursement policies can also help mitigate market limitations.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Clostridium Difficile Treatment Market

The Clostridium Difficile Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of Clostridium difficile infection
    • Focus on preventive strategies and probiotics
    • Increased healthcare awareness and initiatives to treat clostridium difficile infection
  • Market Restraints
    • Antibiotic resistance and recurrence rates
  • Market Opportunities
    • Development of targeted and advanced therapies
    • Advancements in diagnostic tools and techniques
  • Market Challenges
    • Complexity of accurate diagnosis and limitations in regulatory compliance

Porter's Five Forces: A Strategic Tool for Navigating the Clostridium Difficile Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Clostridium Difficile Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Clostridium Difficile Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Clostridium Difficile Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Clostridium Difficile Treatment Market

A detailed market share analysis in the Clostridium Difficile Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Clostridium Difficile Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Clostridium Difficile Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Clostridium Difficile Treatment Market

A strategic analysis of the Clostridium Difficile Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Clostridium Difficile Treatment Market, highlighting leading vendors and their innovative profiles. These include Acurx Pharmaceuticals, Inc., Aridis Pharmaceuticals, Inc., Astellas Pharma Inc., AstraZeneca PLC, GlaxoSmithKlinePLC, Immuron Limited, Merck & Co., Inc., Mylan N.V., Pfizer, Inc., Rebiotix Inc, Roche Holding AG, Seres Therapeutics, Inc., Summit Therapeutics, Inc., Synthetic Biologics, Inc., Thermo Fisher Scientific, Inc., Trinity Biotech PLC, and Vedanta Biosciences, Inc..

Market Segmentation & Coverage

This research report categorizes the Clostridium Difficile Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Antibiotics Treatment and Non-Antibiotic Treatment. The Antibiotics Treatment is further studied across Fidaxomicin, Metronidazole, and Vancomycin. The Non-Antibiotic Treatment is further studied across Fecal Microbiota Transplantation and Probiotics.
  • Based on Route of Administration, market is studied across Oral and Parenteral.
  • Based on Patient Age Group, market is studied across Adults, Geriatric, and Pediatric.
  • Based on End-User, market is studied across Home Healthcare and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of Clostridium difficile infection
      • 5.1.1.2. Focus on preventive strategies and probiotics
      • 5.1.1.3. Increased healthcare awareness and initiatives to treat clostridium difficile infection
    • 5.1.2. Restraints
      • 5.1.2.1. Antibiotic resistance and recurrence rates
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of targeted and advanced therapies
      • 5.1.3.2. Advancements in diagnostic tools and techniques
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity of accurate diagnosis and limitations in regulatory compliance
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: Growing demand for Fidaxomicin to ensure low recurrence rates and minimal disruption to the gut microbiome
    • 5.2.2. End User: Increasing availability of clostridium difficile treatment across hospitals and clinics
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Clostridium Difficile Treatment Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Antibiotics Treatment
    • 6.2.1. Fidaxomicin
    • 6.2.2. Metronidazole
    • 6.2.3. Vancomycin
  • 6.3. Non-Antibiotic Treatment
    • 6.3.1. Fecal Microbiota Transplantation
    • 6.3.2. Probiotics

7. Clostridium Difficile Treatment Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parenteral

8. Clostridium Difficile Treatment Market, by Patient Age Group

  • 8.1. Introduction
  • 8.2. Adults
  • 8.3. Geriatric
  • 8.4. Pediatric

9. Clostridium Difficile Treatment Market, by End-User

  • 9.1. Introduction
  • 9.2. Home Healthcare
  • 9.3. Hospitals & Clinics

10. Americas Clostridium Difficile Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Clostridium Difficile Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Clostridium Difficile Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Vedanta Biosciences advances VE303 in phase III trial to combat recurrent c. difficile infections, eyes market approval, and strategic investments
    • 13.3.2. Acurx Pharmaceuticals advances Ibezapolstat to phase 3 clinical trials following FDA end-of-phase 2 approval for clostridium difficile treatment
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Acurx Pharmaceuticals, Inc.
  • 2. Aridis Pharmaceuticals, Inc.
  • 3. Astellas Pharma Inc.
  • 4. AstraZeneca PLC
  • 5. GlaxoSmithKlinePLC
  • 6. Immuron Limited
  • 7. Merck & Co., Inc.
  • 8. Mylan N.V.
  • 9. Pfizer, Inc.
  • 10. Rebiotix Inc
  • 11. Roche Holding AG
  • 12. Seres Therapeutics, Inc.
  • 13. Summit Therapeutics, Inc.
  • 14. Synthetic Biologics, Inc.
  • 15. Thermo Fisher Scientific, Inc.
  • 16. Trinity Biotech PLC
  • 17. Vedanta Biosciences, Inc.

LIST OF FIGURES

  • FIGURE 1. CLOSTRIDIUM DIFFICILE TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CLOSTRIDIUM DIFFICILE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CLOSTRIDIUM DIFFICILE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CLOSTRIDIUM DIFFICILE TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CLOSTRIDIUM DIFFICILE TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY FIDAXOMICIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY METRONIDAZOLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY VANCOMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY FECAL MICROBIOTA TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PROBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 89. INDIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. INDONESIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. INDONESIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. INDONESIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. INDONESIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 95. INDONESIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. JAPAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. JAPAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. JAPAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. JAPAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. JAPAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 101. JAPAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. MALAYSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. MALAYSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 104. MALAYSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. MALAYSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. MALAYSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 107. MALAYSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. PHILIPPINES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. PHILIPPINES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 110. PHILIPPINES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. PHILIPPINES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. PHILIPPINES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. SINGAPORE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. SINGAPORE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 116. SINGAPORE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 117. SINGAPORE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. SINGAPORE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 119. SINGAPORE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. SOUTH KOREA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. SOUTH KOREA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH KOREA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH KOREA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH KOREA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. TAIWAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. TAIWAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 128. TAIWAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 129. TAIWAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. TAIWAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 131. TAIWAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. THAILAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. THAILAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 134. THAILAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. THAILAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. THAILAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 137. THAILAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. VIETNAM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. VIETNAM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 140. VIETNAM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. VIETNAM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. VIETNAM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 143. VIETNAM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 151. DENMARK CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. DENMARK CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 153. DENMARK CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 154. DENMARK CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. DENMARK CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 156. DENMARK CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. EGYPT CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. EGYPT CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 159. EGYPT CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 160. EGYPT CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. EGYPT CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 162. EGYPT CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. FINLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. FINLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 165. FINLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 166. FINLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. FINLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 168. FINLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. FRANCE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. FRANCE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 171. FRANCE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 172. FRANCE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. FRANCE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 174. FRANCE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. GERMANY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. GERMANY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 177. GERMANY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 178. GERMANY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. GERMANY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 180. GERMANY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. ISRAEL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. ISRAEL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 183. ISRAEL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 184. ISRAEL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. ISRAEL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 186. ISRAEL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. ITALY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. ITALY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 189. ITALY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 190. ITALY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. ITALY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 192. ITALY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 193. NETHERLANDS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. NETHERLANDS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 195. NETHERLANDS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 196. NETHERLANDS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 198. NETHERLANDS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 199. NIGERIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. NIGERIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 201. NIGERIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 202. NIGERIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 203. NIGERIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 204. NIGERIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 205. NORWAY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. NORWAY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 207. NORWAY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 208. NORWAY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 209. NORWAY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 210. NORWAY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 211. POLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. POLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 213. POLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 214. POLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 215. POLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 216. POLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 217. QATAR CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. QATAR CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 219. QATAR CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 220. QATAR CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. QATAR CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 222. QATAR CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 223. RUSSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. RUSSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 225. RUSSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 226. RUSSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 227. RUSSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 228. RUSSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 229. SAUDI ARABIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. SAUDI ARABIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 231. SAUDI ARABIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 232. SAUDI ARABIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 234. SAUDI ARABIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 235. SOUTH AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. SOUTH AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 237. SOUTH AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 241. SPAIN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. SPAIN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 243. SPAIN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 244. SPAIN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 245. SPAIN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 246. SPAIN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 247. SWEDEN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. SWEDEN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 249. SWEDEN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 250. SWEDEN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 251. SWEDEN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 252. SWEDEN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 253. SWITZERLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. SWITZERLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 255. SWITZERLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 256. SWITZERLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 258. SWITZERLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 259. TURKEY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. TURKEY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 261. TURKEY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 262. TURKEY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 263. TURKEY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 264. TURKEY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 265. UNITED ARAB EMIRATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. UNITED ARAB EMIRATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 267. UNITED ARAB EMIRATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 268. UNITED ARAB EMIRATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED KINGDOM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED KINGDOM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED KINGDOM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED KINGDOM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED KINGDOM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 277. CLOSTRIDIUM DIFFICILE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 278. CLOSTRIDIUM DIFFICILE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023